Buck Elizabeth 4

Accession 0001880385-26-000002

CIK 0001701541other

Filed

Jan 22, 7:00 PM ET

Accepted

Jan 23, 4:05 PM ET

Size

5.7 KB

Accession

0001880385-26-000002

AI-generated summary of this filing

Updated Jan 23, 2026

Black Diamond (BDTX) CSO Elizabeth Buck Receives 250,000-Share Award

What Happened

Elizabeth Buck, Chief Scientific Officer of Black Diamond Therapeutics (BDTX), received a derivative award covering 250,000 shares on January 21, 2026. The award is reported at a price of $0.00 (no cash paid reported) and is classified as an acquisition/award (Form 4 code A).

Key Details

Transaction date: 2026-01-21; Form 4 filed: 2026-01-23 (filed within typical 2-business-day window).
Award size: 250,000 shares; reported price/exercise: $0.00.
Shares owned after transaction: not specified in this filing.
Footnote (vesting): 25% of the award vests on January 21, 2027; the remainder vests in 36 equal monthly installments thereafter, subject to continued service.
Transaction type: grant/award (derivative), not an open-market purchase or sale.

Context

This is a compensation grant (derivative award) with a multi-year vesting schedule, so the shares are not immediately transferable or liquid. Such grants are routine for executives and reflect compensation arrangements rather than an outright market buy or sell.

Form 4

Period: 2026-01-21

CHIEF SCIENTIFIC OFFICER

Transactions

Award
Stock Option (Right to Buy)
[F1]
2026-01-21+250,000→ 250,000 total
Exercise: $2.57Exp: 2036-01-20→ Common Stock (250,000 underlying)

Footnotes (1)

[F1]25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Signature

/s/ Brent Hatzis-Schoch, Attorney-in-Fact|2026-01-23

1 file

Black Diamond Therapeutics, Inc.

CIK 0001701541

Entity typeother